Publications

Comparison of outcomes with elranatamab and real world treatments in the UK for triple class exposed relapsed and refractory multiple myeloma (BMC Cancer volume 25, Article number: 1219 (2025))

Back to all resources
Comparison of outcomes with elranatamab and real world treatments in the UK for triple class exposed relapsed and refractory multiple myeloma (BMC Cancer volume 25, Article number: 1219 (2025))